Close

Anti-CD276 (CBFYC-1202) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY2727)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD276 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD276. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD276 antibody linked to 4-1BB(CD137), OX40 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD276
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Skin cancer (SCC)
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells and binds to a high-affinity ligand (4-1BB) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMS, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound.CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • CBFYC-1202
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD276 molecule
  • Synonyms
  • CD276; CD276 molecule; B7H3; B7-H3; B7RP-2; 4Ig-B7-H3

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FuncS

Fig.1 Therapeutic effects of B7-H3 CAR-T cells in tumor xenografts.

CAR Construction : 8H9-4-1BB-CD3ζ Latest CAR Construction

Fig.1 Therapeutic effects of B7-H3 CAR-T cells in tumor xenografts.

Tumor growth in A549-injected mice (b) or HCT 116-injected mice (c) was measured using digital caliper, and tumor area was calculated.

Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18.

Complete CAR data FCM

Fig.2 Cytokine production in B7-H3 CAR and vehicle T cells.

CAR Construction : 8H9-4-1BB-CD3ζ Latest CAR Construction

Fig.2 Cytokine production in B7-H3 CAR and vehicle T cells.

Effector T cells were incubated with target A549 or HCT 116 cells at a ratio of 10:1 for 24 h. The concentrations of cytokines were measured using flow cytometry.

Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18.

Complete CAR data ELISA

Fig.3  Memory cell phenotypes of B7-H3 CAR-T cells.

CAR Construction : 8H9-4-1BB-CD3ζ Latest CAR Construction

Fig.3 Memory cell phenotypes of B7-H3 CAR-T cells.

Expression of CD62L and CCR7 on T cells was identified with staining with anti-CD62L and anti-CCR7 antibodies, respectively, and measured using flow cytometry.

Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18.

Complete CAR data FCM

Fig.4 Degranulation markers in B7-H3 CAR T cells.

CAR Construction : 8H9-4-1BB-CD3ζ Latest CAR Construction

Fig.4 Degranulation markers in B7-H3 CAR T cells.

Expressions of CD107a, intracellular granzyme B and perforin staining on T cells were stained with anti CD107a, granzyme B and perforin antibodies and measured by flow cytometry.

Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18.

CAR scFv data SPR

Fig.5 The binding ability of anti-B7-H3 mAb.

CAR Construction : Latest CAR Construction

Fig.5 The binding ability of anti-B7-H3 mAb.

Binding kinetics of anti-B7-H3 antibody ch8H9 to (2Ig-B7-H3-Fc WT, R127A, and D128A) by surface plasmon resonance.

Ahmed, M., Cheng, M., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H. F., ... & Cheung, N. K. V. (2015). Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. Journal of Biological Chemistry, 290(50), 30018-30029.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD276 (CBFYC-1202) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY2727). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.